Glypican 1/GPC1, His, Human

Glypican 1/GPC1, His, Human

CAR-T cells targeting glypican-1 (GPC1)-specific human and murine CAR-T cells generated from our original anti-human/mouse GPC1 antibody showed strong antitumor effects in xenogeneic and syngeneic mouse models, respectively. Importantly, the murine CAR-T cells enhanced endogenous T cell responses against a non-GPC1 tumor antigen through the mechanism of antigen-spreading and showed synergistic antitumor effects with anti-PD-1 antibody without any adverse effects in syngeneic models.
Z05360
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Glypican 1/GPC1 (Asp24-Ser530)
Accession # P35052-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Glypican 1/GPC1, His, Human at 0.5μg/ml (100μl/well) on the plate can bind Anti­Glypican 1 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 57.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-135 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background CAR-T cells targeting glypican-1 (GPC1)-specific human and murine CAR-T cells generated from our original anti-human/mouse GPC1 antibody showed strong antitumor effects in xenogeneic and syngeneic mouse models, respectively. Importantly, the murine CAR-T cells enhanced endogenous T cell responses against a non-GPC1 tumor antigen through the mechanism of antigen-spreading and showed synergistic antitumor effects with anti-PD-1 antibody without any adverse effects in syngeneic models.
Synonyms Glypican-1; FLJ38078; GPC1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.